Literature DB >> 12470670

Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones.

Françoise Lasne1, Laurent Martin, Nathalie Crepin, Jacques de Ceaurriz.   

Abstract

Erythropoietin (EPO) is normally present in urine at a low concentration (about 1IU/L, i.e., about 10ng/L) for a total protein concentration of at least 50mg/L. A method to study the isoelectric profile of this hormone from 20-ml urine aliquots without previous purification was developed. This method involves isoelectric focusing of the retentate from ultrafiltered urine. Both the ultrafiltration and the isoelectric focusing required precautionary measures to prevent EPO degradation by the proteases that are present in urine. Because classical immunoblotting gave rise to an unspecific detection of various urinary proteins in the focused retentate, it was essential to use the "double-blotting" process developed to solve this problem. Sufficient sensitivity was achieved using amplified chemiluminiscent detection after the blotting membrane was treated with dithiotreitol. The patterns that were revealed from various urinary samples proved to be highly heterogeneous as they were composed of more than 10 isoforms in a pI range of 3.7-4.7. Clear transformation of the patterns was observed in the case of treatment by the recombinant hormone, suggesting that this method can be regarded an efficient tool for indicating recombinant EPO misuse in sports. It may also open new investigations in the field of physiologic or pathologic exploration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12470670     DOI: 10.1016/s0003-2697(02)00407-4

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  23 in total

Review 1.  The evolving science of detection of 'blood doping'.

Authors:  Carsten Lundby; Paul Robach; Bengt Saltin
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Erythropoietin down-regulates proximal renal tubular reabsorption and causes a fall in glomerular filtration rate in humans.

Authors:  Niels Vidiendal Olsen; Niels-Jacob Aachmann-Andersen; Peter Oturai; Thor Munch-Andersen; Andreas Bornø; Carl Hulston; Niels-Henrik Holstein-Rathlou; Paul Robach; Carsten Lundby
Journal:  J Physiol       Date:  2010-08-19       Impact factor: 5.182

3.  Erythropoietin and blood doping.

Authors:  N Robinson; S Giraud; C Saudan; N Baume; L Avois; P Mangin; M Saugy
Journal:  Br J Sports Med       Date:  2006-07       Impact factor: 13.800

4.  Detection of continuous erythropoietin receptor activator in blood and urine in anti-doping control.

Authors:  Françoise Lasne; Laurent Martin; Jean Antoine Martin; Jacques de Ceaurriz
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

5.  Illicit organogenesis: Methods and substances of doping and manipulation.

Authors:  Mario Thevis; Wilhelm Schänzer
Journal:  Organogenesis       Date:  2008-10       Impact factor: 2.500

Review 6.  Gene doping: gene delivery for olympic victory.

Authors:  David Gould
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

Review 7.  Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.

Authors:  Harrison G Pope; Ruth I Wood; Alan Rogol; Fred Nyberg; Larry Bowers; Shalender Bhasin
Journal:  Endocr Rev       Date:  2013-12-17       Impact factor: 19.871

Review 8.  Erythropoietin abuse and erythropoietin gene doping: detection strategies in the genomic era.

Authors:  Evanthia Diamanti-Kandarakis; Panagiotis A Konstantinopoulos; Joanna Papailiou; Stylianos A Kandarakis; Anastasios Andreopoulos; Gerasimos P Sykiotis
Journal:  Sports Med       Date:  2005       Impact factor: 11.136

Review 9.  From gene engineering to gene modulation and manipulation: can we prevent or detect gene doping in sports?

Authors:  Giuseppe Fischetto; Stéphane Bermon
Journal:  Sports Med       Date:  2013-10       Impact factor: 11.136

Review 10.  Erythropoiesis-stimulating agents and other methods to enhance oxygen transport.

Authors:  S Elliott
Journal:  Br J Pharmacol       Date:  2008-03-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.